LIVIVO - Search results -

Search results

Result 1 - 9 of total 9

Search options

Article: Publication ethics during the Covid times: Reflections on research integrity, authorship, peer review and editorial policies.

Kuttiatt, Vijesh Sreedhar / Menon, Ramesh P / Kumar, Ashwani

2022 Volume 35, Issue 3, Page(s) 177–179

MeSH term(s)	Humans ; Authorship ; Editorial Policies ; COVID-19/epidemiology ; COVID-19/prevention & control ; Peer Review
Language	English
Publishing date	2022-12-03
Publishing country	India
Document type	Journal Article
ZDB-ID	645116-0
ISSN	0970-258X
ISSN	0970-258X
DOI	10.25259/NMJI-35-3-177
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2493: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evaluation of the mosquitocidal efficacy of fluralaner, a potential candidate for drug based vector control.

Shah, Harish Kumar / Srinivasan, Vaishnavi / Venkatesan, Shakila / Balakrishnan, Vijayakumar / Candasamy, Sadanandane / Mathew, Nisha / Kumar, Ashwani / Kuttiatt, Vijesh Sreedhar

Scientific reports

2024 Volume 14, Issue 1, Page(s) 5628

Abstract: Vector control is a key intervention against mosquito borne diseases. However, conventional methods have several limitations and alternate strategies are in urgent need. Vector control with endectocides such as ivermectin is emerging as a novel strategy. ...

Abstract	Vector control is a key intervention against mosquito borne diseases. However, conventional methods have several limitations and alternate strategies are in urgent need. Vector control with endectocides such as ivermectin is emerging as a novel strategy. The short half-life of ivermectin is a limiting factor for its application as a mass therapy tool for vector control. Isoxazoline compounds like fluralaner, a class of veterinary acaricides with long half-life hold promise as an alternative. However, information about their mosquitocidal effect is limited. We explored the efficacy of fluralaner against laboratory reared vector mosquitoes-Aedes aegypti, Anopheles stephensi, and, Culex quinquefasciatus. 24 h post-blood feeding, fluralaner showed a significant mosquitocidal effect with LC
MeSH term(s)	Animals ; Ivermectin/pharmacology ; Insecticides/pharmacology ; Mosquito Vectors ; Larva ; Culex ; Anopheles ; Aedes ; Plant Extracts/pharmacology ; Isoxazoles
Chemical Substances	Ivermectin (70288-86-7) ; A1443 compound ; Insecticides ; Plant Extracts ; Isoxazoles
Language	English
Publishing date	2024-03-07
Publishing country	England
Document type	Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-024-56053-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Coronavirus disease 2019 in children: Clinical & epidemiological implications.

Kuttiatt, Vijesh Sreedhar / Abraham, Philip Raj / Menon, Ramesh P / Vaidya, Pankaj C / Rahi, Manju

The Indian journal of medical research

2020 Volume 152, Issue 1 & 2, Page(s) 21–40

Abstract: Despite the global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there are limited data emerging in children. This review provides an update on clinical features, diagnosis, epidemiology, management and prevention ... ...

Abstract	Despite the global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there are limited data emerging in children. This review provides an update on clinical features, diagnosis, epidemiology, management and prevention of coronavirus disease 2019 (COVID-19) in children. Specific characteristics noted in children and their implications in disease management as well as transmission control are highlighted. Besides respiratory symptoms, gastrointestinal and atypical features such as chilblains, neurological symptoms and multisystem inflammation are also reported. Younger infants and those with comorbidity were found to be at risk of severe illness. Infected pregnant women and neonates were reported to have good prognosis. It is possible to manage the children with mild disease at home, with strict infection prevention control measures; severely affected require respiratory support and intensive care management. There are anecdotal reports of using antiviral and immunomodulatory drugs, benefit of which needs to be confirmed in clinical trials. A significant percentage of asymptomatic infection in children has epidemiological implication as these may act as links in transmission chain in the community. There is a need for systematic data on extra-pulmonary manifestations and atypical features, risk factors of severity, role of imaging and biomarkers, testing and management strategies and trials with antivirals and immunomodulatory drugs in children. The psychosocial effects of quarantine, closure of schools, lack of play activities and impact of lockdown need to be addressed. Understanding the biological basis for the profound age-dependent differential outcome of COVID-19 infection is important. Elucidating the protective mechanisms in children may aid in developing novel treatment strategies.
MeSH term(s)	Betacoronavirus/drug effects ; Betacoronavirus/pathogenicity ; COVID-19 ; Child ; Comorbidity ; Coronavirus Infections/epidemiology ; Coronavirus Infections/pathology ; Coronavirus Infections/therapy ; Coronavirus Infections/virology ; Female ; Humans ; Infant, Newborn ; Pandemics ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/pathology ; Pneumonia, Viral/therapy ; Pneumonia, Viral/virology ; Pregnancy ; Pregnancy Complications, Infectious/epidemiology ; Pregnancy Complications, Infectious/pathology ; Pregnancy Complications, Infectious/therapy ; Pregnancy Complications, Infectious/virology ; Risk Factors ; SARS-CoV-2
Keywords	covid19
Language	English
Publishing date	2020-08-10
Publishing country	India
Document type	Journal Article ; Review
ZDB-ID	390883-5
ISSN	0971-5916 ; 0019-5340
ISSN	0971-5916 ; 0019-5340
DOI	10.4103/ijmr.IJMR_977_20
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.143: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Coronavirus disease 2019 in children

Vijesh Sreedhar Kuttiatt / Philip Raj Abraham / Ramesh P Menon / Pankaj C Vaidya / Manju Rahi

Indian Journal of Medical Research, Vol 152, Iss 1, Pp 21-

Clinical & epidemiological implications

2020 Volume 40

Abstract	Despite the global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there are limited data emerging in children. This review provides an update on clinical features, diagnosis, epidemiology, management and prevention of coronavirus disease 2019 (COVID-19) in children. Specific characteristics noted in children and their implications in disease management as well as transmission control are highlighted. Besides respiratory symptoms, gastrointestinal and atypical features such as chilblains, neurological symptoms and multisystem inflammation are also reported. Younger infants and those with comorbidity were found to be at risk of severe illness. Infected pregnant women and neonates were reported to have good prognosis. It is possible to manage the children with mild disease at home, with strict infection prevention control measures; severely affected require respiratory support and intensive care management. There are anecdotal reports of using antiviral and immunomodulatory drugs, benefit of which needs to be confirmed in clinical trials. A significant percentage of asymptomatic infection in children has epidemiological implication as these may act as links in transmission chain in the community. There is a need for systematic data on extra-pulmonary manifestations and atypical features, risk factors of severity, role of imaging and biomarkers, testing and management strategies and trials with antivirals and immunomodulatory drugs in children. The psychosocial effects of quarantine, closure of schools, lack of play activities and impact of lockdown need to be addressed. Understanding the biological basis for the profound age-dependent differential outcome of COVID-19 infection is important. Elucidating the protective mechanisms in children may aid in developing novel treatment strategies.
Keywords	children - clinical features - covid-2019 - epidemiology - prevention - sars-cov-2 - severity of illness - treatment ; Medicine ; R ; covid19
Subject code	610 ; 360
Language	English
Publishing date	2020-01-01T00:00:00Z
Publisher	Wolters Kluwer Medknow Publications
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Frequency and Clinical Significance of Localized Adverse Events following Mass Drug Administration for Lymphatic Filariasis in an Endemic Area in South India.

Kuttiatt, Vijesh Sreedhar / Somani, Roopali K / Swaminathan, Subramanian / Krishnamoorthy, Kaliannagounder / Weil, Gary J / Purushothaman, Jambulingam

The American journal of tropical medicine and hygiene

2019 Volume 102, Issue 1, Page(s) 96–99

Abstract: Fear of adverse events (AEs) negatively affects compliance to mass drug administration (MDA) for lymphatic filariasis (LF) elimination program. Systemic AEs are believed to occur because of killing of microfilariae, whereas localized soft tissue ... ...

Abstract	Fear of adverse events (AEs) negatively affects compliance to mass drug administration (MDA) for lymphatic filariasis (LF) elimination program. Systemic AEs are believed to occur because of killing of microfilariae, whereas localized soft tissue reactions might be due to the death of adult worms following therapy. Most AEs are mild and self-limited. However, localized AEs are sometimes more significant and of concern to participants. Here, we describe localized AEs that were noted during a large community study that evaluated the safety of a triple-drug regimen (ivermectin, diethylcarbamazine, and albendazole) for the treatment of LF in India. We have also discussed the importance of timely detection and careful management of AEs for preserving community confidence in MDA.
MeSH term(s)	Adolescent ; Adult ; Albendazole/administration & dosage ; Albendazole/adverse effects ; Albendazole/therapeutic use ; Anthelmintics/administration & dosage ; Anthelmintics/adverse effects ; Anthelmintics/therapeutic use ; Diethylcarbamazine/administration & dosage ; Diethylcarbamazine/adverse effects ; Diethylcarbamazine/therapeutic use ; Drug Therapy, Combination/adverse effects ; Elephantiasis, Filarial/prevention & control ; Female ; Humans ; India/epidemiology ; Ivermectin/administration & dosage ; Ivermectin/adverse effects ; Ivermectin/therapeutic use ; Male ; Mass Drug Administration
Chemical Substances	Anthelmintics ; Ivermectin (70288-86-7) ; Albendazole (F4216019LN) ; Diethylcarbamazine (V867Q8X3ZD)
Language	English
Publishing date	2019-11-26
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2942-7
ISSN	1476-1645 ; 0002-9637
ISSN (online)	1476-1645
ISSN	0002-9637
DOI	10.4269/ajtmh.19-0532
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.61: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Coronavirus disease 2019 in children: Clinical & epidemiological implications

Kuttiatt, Vijesh Sreedhar / Abraham, Philip Raj / Menon, Ramesh P / Vaidya, Pankaj C / Rahi, Manju

Indian J Med Res

Abstract	Despite the global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there are limited data emerging in children. This review provides an update on clinical features, diagnosis, epidemiology, management and prevention of coronavirus disease 2019 (COVID-19) in children. Specific characteristics noted in children and their implications in disease management as well as transmission control are highlighted. Besides respiratory symptoms, gastrointestinal and atypical features such as chilblains, neurological symptoms and multisystem inflammation are also reported. Younger infants and those with comorbidity were found to be at risk of severe illness. Infected pregnant women and neonates were reported to have good prognosis. It is possible to manage the children with mild disease at home, with strict infection prevention control measures; severely affected require respiratory support and intensive care management. There are anecdotal reports of using antiviral and immunomodulatory drugs, benefit of which needs to be confirmed in clinical trials. A significant percentage of asymptomatic infection in children has epidemiological implication as these may act as links in transmission chain in the community. There is a need for systematic data on extra-pulmonary manifestations and atypical features, risk factors of severity, role of imaging and biomarkers, testing and management strategies and trials with antivirals and immunomodulatory drugs in children. The psychosocial effects of quarantine, closure of schools, lack of play activities and impact of lockdown need to be addressed. Understanding the biological basis for the profound age-dependent differential outcome of COVID-19 infection is important. Elucidating the protective mechanisms in children may aid in developing novel treatment strategies.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #708848
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.

Jambulingam, Purushothaman / Kuttiatt, Vijesh Sreedhar / Krishnamoorthy, Kaliannagounder / Subramanian, Swaminathan / Srividya, Adinarayanan / Raju, Hari Kishan K / Rahi, Manju / Somani, Roopali K / Suryaprakash, Mallanna K / Dwivedi, Gangeshwar P / Weil, Gary J

PLoS neglected tropical diseases

2021 Volume 15, Issue 2, Page(s) e0009069

Abstract: Background: Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, ... ...

Abstract	Background: Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamazine and albendazole) or DA (diethylcarbamazine and albendazole) in India. Methodology/principal findings: This two-armed, open-labelled, block randomised, community study was conducted in LF endemic villages in Yadgir district, Karnataka, India. Consenting participants ≥5 years of age were tested for circulating filarial antigenemia (CFA) and microfilaremia (Mf) before treatment with a single oral dose of IDA or DA. Adverse events (AEs) were monitored actively for two days and passively for five more days. Persons with positive CFA or Mf tests at baseline were retested 12-months post-treatment to assess treatment efficacy. Baseline CFA and Mf-rates were 26.4% and 6.9% in IDA and 24.5% and 6.4% in DA villages respectively. 4758 and 4160 participants received IDA and DA. Most AEs were mild after both treatments; fewer than 0.1% of participants experienced AEs with severity > grade 1. No serious AEs were observed. Fever, headache and dizziness were the most common AEs. AE rates were slightly higher after IDA than DA (8.3% vs. 6.4%, P<0.01). AEs were more frequent in females and Mf-positives after either treatment, but significantly more frequent after IDA (40.5% vs 20.2%, P < 0.001). IDA was more effective for clearing Mf than DA (84% vs. 61.8%, P < 0.001). Geometric mean Mf counts per 60μl in retested Mf-positives decreased by 96.4% from 11.8 after IDA and by 90.0% from 9.5 after DA. Neither treatment was effective for clearing CFA. Conclusions/significance: IDA had an acceptable safety profile and was more effective for clearing Mf than DA. With adequate compliance and medical support to manage AEs, IDA has the potential to accelerate LF elimination in India. Trial registration: Clinical Trial Registry of India (CTRI No/2016/10/007399).
MeSH term(s)	Adolescent ; Adult ; Albendazole/administration & dosage ; Albendazole/adverse effects ; Animals ; Child ; Diethylcarbamazine/administration & dosage ; Diethylcarbamazine/adverse effects ; Drug-Related Side Effects and Adverse Reactions ; Elephantiasis, Filarial/drug therapy ; Female ; Filaricides/administration & dosage ; Filaricides/adverse effects ; Humans ; India ; Ivermectin/administration & dosage ; Ivermectin/adverse effects ; Male ; Mass Drug Administration ; Wuchereria bancrofti/immunology ; Wuchereria bancrofti/isolation & purification
Chemical Substances	Filaricides ; Ivermectin (70288-86-7) ; Albendazole (F4216019LN) ; Diethylcarbamazine (V867Q8X3ZD)
Language	English
Publishing date	2021-02-16
Publishing country	United States
Document type	Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
ZDB-ID	2429704-5
ISSN	1935-2735 ; 1935-2727
ISSN (online)	1935-2735
ISSN	1935-2727
DOI	10.1371/journal.pntd.0009069
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.

Purushothaman Jambulingam / Vijesh Sreedhar Kuttiatt / Kaliannagounder Krishnamoorthy / Swaminathan Subramanian / Adinarayanan Srividya / Hari Kishan K Raju / Manju Rahi / Roopali K Somani / Mallanna K Suryaprakash / Gangeshwar P Dwivedi / Gary J Weil

PLoS Neglected Tropical Diseases, Vol 15, Iss 2, p e

2021 Volume 0009069

Abstract: Background Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, ... ...

Abstract	Background Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamazine and albendazole) or DA (diethylcarbamazine and albendazole) in India. Methodology/principal findings This two-armed, open-labelled, block randomised, community study was conducted in LF endemic villages in Yadgir district, Karnataka, India. Consenting participants ≥5 years of age were tested for circulating filarial antigenemia (CFA) and microfilaremia (Mf) before treatment with a single oral dose of IDA or DA. Adverse events (AEs) were monitored actively for two days and passively for five more days. Persons with positive CFA or Mf tests at baseline were retested 12-months post-treatment to assess treatment efficacy. Baseline CFA and Mf-rates were 26.4% and 6.9% in IDA and 24.5% and 6.4% in DA villages respectively. 4758 and 4160 participants received IDA and DA. Most AEs were mild after both treatments; fewer than 0.1% of participants experienced AEs with severity > grade 1. No serious AEs were observed. Fever, headache and dizziness were the most common AEs. AE rates were slightly higher after IDA than DA (8.3% vs. 6.4%, P<0.01). AEs were more frequent in females and Mf-positives after either treatment, but significantly more frequent after IDA (40.5% vs 20.2%, P < 0.001). IDA was more effective for clearing Mf than DA (84% vs. 61.8%, P < 0.001). Geometric mean Mf counts per 60μl in retested Mf-positives decreased by 96.4% from 11.8 after IDA and by 90.0% from 9.5 after DA. Neither treatment was effective for clearing CFA. Conclusions/significance IDA had an acceptable safety profile and was more effective for clearing Mf than DA. With adequate compliance and medical support to manage AEs, IDA has the potential to accelerate LF elimination in India. Trial registration Clinical Trial Registry of India (CTRI No/2016/10/007399).
Keywords	Arctic medicine. Tropical medicine ; RC955-962 ; Public aspects of medicine ; RA1-1270
Subject code	150
Language	English
Publishing date	2021-02-01T00:00:00Z
Publisher	Public Library of Science (PLoS)
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India.

Neogi, Ujjwal / Prarthana, B S / Gupta, Soham / D'souza, George / De Costa, Ayesha / Kuttiatt, Vijesh Sreedhar / Arumugam, Karthika / Shet, Anita

AIDS research and human retroviruses

2010 Volume 26, Issue 10, Page(s) 1097–1101

Abstract: Although India has a large burden of HIV infection, good access to first-line antiretroviral therapy is widely available. However, understanding HIV resistance-associated mutations and polymorphisms is critical for continued success. The RT region of the ...

Abstract	Although India has a large burden of HIV infection, good access to first-line antiretroviral therapy is widely available. However, understanding HIV resistance-associated mutations and polymorphisms is critical for continued success. The RT region of the HIV-1 pol gene was studied among 21 ART-naive HIV-1-infected individuals from South India. In addition, 421 published Indian HIV-1 subtype C sequences were analyzed for time trends in polymorphism frequency. Among primary isolates, all HIV-1 isolates were subtype C, and drug-resistant mutations were identified among two (9.56%) subjects. Mutations included E138A (etravirine resistance associated) and L210LS (thymidine analog mutation). The overall frequency of specific polymorphisms was similar to frequencies reported from different regions of India. Novel mutations were observed at positions Q23P/H and A129AG among isolates from our clinical cohort. Over a span of 10 years, the median polymorphism frequency among ART-naive subjects has remained unchanged, suggesting the slow evolution of HIV-1 subtype C in India.
MeSH term(s)	Adult ; Antiretroviral Therapy, Highly Active ; Cohort Studies ; Drug Resistance, Multiple, Viral/genetics ; Evolution, Molecular ; Female ; HIV Infections/drug therapy ; HIV Reverse Transcriptase/genetics ; HIV-1/drug effects ; HIV-1/genetics ; HIV-1/isolation & purification ; Humans ; India/epidemiology ; Male ; Middle Aged ; Molecular Sequence Data ; Phylogeny ; Polymorphism, Genetic ; Pyridazines/therapeutic use ; RNA, Viral/genetics ; Sequence Analysis, RNA ; Thymidine/therapeutic use ; pol Gene Products, Human Immunodeficiency Virus/genetics
Chemical Substances	Pyridazines ; RNA, Viral ; pol Gene Products, Human Immunodeficiency Virus ; etravirine (0C50HW4FO1) ; HIV Reverse Transcriptase (EC 2.7.7.49) ; Thymidine (VC2W18DGKR)
Language	English
Publishing date	2010-10
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	639130-8
ISSN	1931-8405 ; 0889-2229
ISSN (online)	1931-8405
ISSN	0889-2229
DOI	10.1089/aid.2010.0092
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1928: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito